Pilot Projects for RNAi Screening
DEADLINE: February 26, 2018
The Case Comprehensive Cancer Center is providing collaborative support for projects that focus on the use of RNAi-based screens to identify novel mechanisms underlying cancer biology. RNA-targeted screens have proven to be an effective approach for identifying new pathways involved in cancer initiation, progression, and therapeutic resistance. To facilitate the adoption of such methodologies by its members, the Case CCC will support new projects to be conducted in collaboration with the Small Molecule Drug Development Shared Resource. The Case CCC will supply the requested targeted RNAi library through the screening core and assume screening core costs. Awardees will be expected to commit substantial effort of a lab member to facilitate development of an assay, validate hits, and generate mechanistic data (supported by funds from the Case CCC member). Proposals should be focused on innovative questions, identify a proposed targeted and arrayed RNAi library (full-genome libraries are not responsive to the RFA), describe a feasible high-throughput assay, and have a clear plan for validation of hits. A plan for future analyses of identified candidate genes is also expected, but not specifically supported by this RFA.
- Funding for an RNAi screening project that is focused on a key question in cancer biology.
- Total funds committed to this RFA are $50,000 with the potential of funding 1-2 projects.
- Assay development and screening should occur within 6 months, with 6 months for validation/follow-up experimentation.
- Awarded investigator(s) must commit at least 0.5 FTE of laboratory personnel to this project who will work in collaboration with the core to develop and conduct the screen.
- The targeted and arrayed library will be purchased and the screen developed and completed by the Small Molecule Drug Development Shared Resource.
- Innovative project from a Case Comprehensive Cancer Center member.
- Presentation of a feasible screen that will address a specific question.
- Clear commitment to working with the Small Molecule Drug Discovery Shared Resource to conduct the screen.
- PI must be at the rank of Assistant Professor or higher at CWRU at the time of submission.
- Commitment of personnel to develop/conduct the screen.
- Projects must have a high likelihood of subsequent national-level funding—prior awardees of pilot grants should have a demonstrated track record for garnering nationally competitive funds using data from those pilots.
- While investigators can be collaborators on multiple applications, only one application will be accepted per lead PI.
- Case CCC Pilot Application Cover Page [View PDF: Case CCC-pilot-app-cover-template]
- Case CCC Pilot Application Budget Form [View PDF: CaseCCC-pilot-app-budget-form-singleyr]
- Instructions [View PDF: RFAi-Screening-instructions-2018]
John Pounardjian, Cancer Center Administration: 216.844.8326, email@example.com
Request for Proposals for Case CCC Funding for Pilot/Phase I Clinical Trials
The Case CCC is encouraging investigators to submit Letters of Intent (LOI) for Early Phase Clinical Research Support (EPCRS) funding. These in-house funds are available for the conduct of early phase clinical trials of relatively short duration. Priority will be given to trials which are developed jointly between UH and CCF with planned accrual at both institutions.
The proposals are being accepted on a rolling basis subject to availability of funds.
Please direct any questions and/or submit LOIs to Katarzyna Karelus, Case CCC Clinical Research Office, firstname.lastname@example.org, 216.844.4176.